Skip to Main Content
An official website of the United States government

Approved Projects

Here you can browse the complete list of projects on CDAS whose requests for data/biospecimens were approved.

Filter results of approved projects table below

Showing Most Recent
1-20 of 2752
Approved Projects
Name Principal Investigator Institution Study Date Approved Project ID
Outcomes of men aged ≥60 years old with moderately elevated PSA (1–20 ng/mL) in the PLCO cancer screening trial Scott Eggener University of California, Los Angeles PLCO Oct 5, 2026 PLCO-2084
Incidence of Upper Tract Urothelial Carcinoma in Relation to Smoking, Analgesic Use, and Medical History in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Jonathan Hofmann Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health PLCO Sep 28, 2026 PLCO-2085
Quantitative Analysis of H&E Histopathology and Cancer Outcomes in PLCO James Kelley Pictor Labs. Inc. PLCO Sep 28, 2026 PLCOI-2081
Preliminary Evaluation and Comparative Analysis of Lung Cancer Risk Prediction Approaches Using NLST Low-Dose CT and Clinical Data Doyeon Lee Hecto NLST Sep 28, 2026 NLST-1526
A nested case-control study of serum concentrations of per- and polyfluoroalkyl substances and thyroid cancer risk among military aviators and aviation support personnel Jonathan Hofmann National Cancer Institute MACS Sep 24, 2026 2026-0134
Analytical Suitability and Storage-Stability Pilot for a Serum NMR-Based Multi-Omics Multi-Cancer Early Detection Assay Using Pre-Diagnostic PLCO Specimens PATRICK STRASSER Wholomics GmbH PLCO Sep 15, 2026 2026-0185
The Population Attributable Fractions of Pancreatic Cancer Caused by Key Risk Factors (continuation of PLCO-351) Rachael Stolzenberg-Solomon NCI, NIH PLCO Sep 10, 2026 PLCO-2083
Quantifiable TCR repertoire changes in pre-diagnostic blood specimens among high-grade ovarian cancer patients Bo Li Children's Hospital of Philadelphia PLCO Sep 10, 2026 2025-0079
Integration of omics data and lifestyle factors to assess lung cancer risk among former smokers Xiao Ou Shu Vanderbilt University Medical Center PLCO Sep 10, 2026 2025-0054
Prostate Cancer Risk Stratification Using Needle Core Biopsy or Radical Prostatectomy Specimens (Continuation of PLCOI-2074) Uttara Joshi AIRA Matrix Private Limited PLCO Sep 8, 2026 PLCOI-2080
Evaluating the Impact of Differential LDCT Screening Uptake, Adherence, and Novel Treatment Access on Racial/Ethnic Disparities in Lung Cancer Outcomes: A Modeling Study Michael Leo Oregon Health & Science University PLCO Sep 8, 2026 PLCO-2072
Artificial Intelligence (AI)-Assisted Health Informatics to Stratify Population for Early Screening of Cancer (Sibling Project to PLCO-2067) Gregory Hart University of Guam PLCO Aug 31, 2026 PLCO-2078
Estimating lung cancer screening as treatment guidelines change Jon Steingrimsson Brown University NLST Aug 31, 2026 NLST-1531
Evaluate Artera’s Deep Learning clinical-histologic system as a prognostic classifier for colorectal cancer patients Douglas Peters Artera Inc. PLCO Aug 24, 2026 PLCOI-2073
External Validation of Foundation Model-Derived Histologic Phenotypes in Prostate Pathology Images Olmo Zavala Romero Florida State University PLCO Aug 24, 2026 PLCOI-2063
Parameter-Efficient Fine-Tuning of a 3D CT Foundation Model for Lung Cancer Risk Prediction Akash Pattnaik HOPPR AI NLST Aug 24, 2026 NLST-1528
Explanation-Based Selective Referral in Bimodal Lung Cancer Risk Prediction Using Clinical and Low-Dose CT Data Abdul Sadka Aston University NLST Aug 24, 2026 NLST-1529
Digital Twin–Enabled Prediction of Toxicity and Tumor Control in Prostate Cancer Radiotherapy Samantha Rincon Sabatino InfotechSoft PLCO Aug 24, 2026 PLCOI-2075
Diagnostic Pathways for Lung Cancer Pamela Marcus NCI NLST Aug 20, 2026 NLST-1523
Multi-Omics Profiling of Per- and Polyfluoroalkyl Substances and Chemical Exposures in Relation to Bladder and Upper Tract Urothelial Cancer Risk Jongeun Rhee Henry M. Jackson Foundation for the Advancement of Military Medicine (Center for Prostate Disease Research, Murtha Cancer Center Research Program) MACS Aug 17, 2026 2026-0140